Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14043658 | 0.79 | MAOA (0.38) | HSD17B10TDP1POLBSMN1; SMN2MAPT | |
| SCHEMBL4096667 | 0.71 | ALOX5 (0.37) | KDM4EPOLBTHRBHPGDRECQL | |
| SCHEMBL4325934 | 0.70 | HSD17B10 (0.53) | HSD17B10KDM4ETDP1POLBALOX15 | |
| SCHEMBL11034753 | 0.70 | HSD17B10 (0.61) | HSD17B10KDM4ETDP1POLBALOX15 | |
| SCHEMBL28768922 | 0.70 | HSD17B10 (0.53) | HSD17B10KDM4ETDP1POLBALOX15 | |
| SCHEMBL24125191 | 0.70 | CREBBP (0.57) | HSD17B10KDM4ETDP1POLBALOX15 | |
| SCHEMBL2745305 | 0.70 | CREBBP (0.57) | HSD17B10KDM4ETDP1POLBALOX15 | |
| SCHEMBL9024189 | 0.70 | HSD17B10 (0.53) | HSD17B10KDM4ETDP1POLBALOX15 | |
| SCHEMBL31542005 | 0.70 | HSD17B10 (0.53) | HSD17B10KDM4ETDP1POLBALOX15 | |
| SCHEMBL8368558 | 0.70 | HSD17B10 (0.49) | HSD17B10KDM4ETDP1POLBALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902355-B2 | Condensation of 10H-dibenzo-[b,f][1,4]-thiazepin-11-one with a piperazine derivative in the presence of a titanium alkoxide catalyst; Titanium catalyst easier to handle, have low toxicity, not chlorinated, much less harmful for the environment | UNION QUIMICO-FARMACEUTICA S.A. (ES) | 2011-03-08 | — | — | US | disclosed |
| US-7687622-B2 | Process for preparing quetiapine fumarate | TEVA PHARMACEUTICAL INDUSTRIES, LTD (IL) | 2010-03-30 | — | — | US | disclosed |
| WO-2008121415-A2 | IMPROVED PROCESS FOR PREPARING QUETIAPINE FUMARATE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-10-09 | — | — | WO | disclosed |
| US-20080171869-A1 | Process For The Preparation Of An 11-(4-Substituted-I- Piperazinyl)Dibenzo[B,F][1,4:rsqb; Thiazepine Derivative | UNION QUIMICO-FARMACEUTICA S.A. (ES) | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171869-A1 | Process For The Preparation Of An 11-(4-Substituted-I- Piperazinyl)Dibenzo[B,F][1,4:rsqb; Thiazepine Derivative | SDHB, SDHA, CYP2F1 | HSD17B10 135/4885KDM4E 683/4885TDP1 2985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.